Virtu Financial’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Virtu Financial’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-126,209	Closed	-$233K	–	2391
2023 Q1	$233K	Buy	126,209 +114,894	+1,015%	+$142K	0.02%	670
2022 Q4	$13K	Buy	+11,315	New	+$16.1K	﹤0.01%	1352
2019 Q1	–	Sell	-32,995	Closed	-$111K	–	1995
2018 Q4	$111K	Buy	+32,995	New	+$154K	0.01%	1108
2018 Q3	–	Sell	-28,378	Closed	-$217K	–	2373
2018 Q2	$217K	Buy	+28,378	New	+$409K	0.01%	1445

Other funds holding JNCE

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Virtu Financial's JNCE Position: Q2 2023 in Review

Virtu Financial sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 126,209 shares — an estimated $233K sold.

Virtu Financial first reported a position in JNCE in Q2 2018 and held it in 4 quarters. The position peaked at $233K in Q1 2023. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

Virtu Financial reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Virtu Financial sold 126,209 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $233K.
Virtu Financial first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2018 and held it in 4 quarters.
Virtu Financial's Jounce Therapeutics, Inc. Common Stock position peaked at $233K in Q1 2023.
1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Virtu Financial's 13F filing for Q2 2023, filed 27 Jul 2023.